Scintillation proximity assay for DNA binding by human p53

被引:5
作者
Gal, Susannah [1 ]
Cook, Jeffery R.
Howells, Leighton
机构
[1] SUNY Binghamton, Dept Biol Sci, Binghamton, NY 13902 USA
[2] BioLife Solut, Binghamton, NY USA
[3] Johnson & Johnson Pharmaceut Res & Dev, Raritan, NJ USA
[4] GE Healthcare, Piscataway, NJ USA
关键词
D O I
10.2144/000112222
中图分类号
Q5 [生物化学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Many DNA binding proteins are known to regulate gene expression. When that binding is altered, a disease state can result. A common method for measuring DNA binding, namely electrophoretic mobility shift assay (EMSA) is often used but it is not amenable to rapid screening of man), samples. As an alternative method, we have developed a DNA binding assay for the tumor suppressor protein p53 in a 96-well microtiter plate format using scintillation proximity assay (SPA) beads. We have shown this assay to be sensitive (as little as 0.5 ng p53 can be detected), quick (assay completed in as little as 15 min), and easily quantitated using a microtiter plate scintillation counter We also used the assay to analyze the kinetics of the DNA binding to p53. The specificity (if this p53 DNA binding SPA was confirmed using competition by oligonucleotides either from the same gene or from mutated versions of this sequence. Thus, SPA is a good alternative to gel shift assays for DNA binding and may be useful for the analysis of multiple tumor cell samples or for high-throughput screens for compounds affecting DNA binding by proteins of interest.
引用
收藏
页码:303 / +
页数:6
相关论文
共 26 条
[1]
Abarzua P, 1996, ONCOGENE, V13, P2477
[2]
WGA-coated yttrium oxide beads enable an imaging-based adenosine 2a receptor binding scintillation proximity assay suitable for high throughput screening [J].
Bryant, R ;
McGuinness, D ;
Turek-Etienne, T ;
Guyer, D ;
Yu, LM ;
Howells, L ;
Caravano, J ;
Zhai, Y ;
Lachowicz, J .
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES, 2004, 2 (03) :290-299
[3]
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound [J].
Bykov, VJN ;
Issaeva, N ;
Shilov, A ;
Hultcrantz, M ;
Pugacheva, E ;
Chumakov, P ;
Bergman, J ;
Wiman, KG ;
Selivanova, G .
NATURE MEDICINE, 2002, 8 (03) :282-288
[4]
CRYSTAL-STRUCTURE OF A P53 TUMOR-SUPPRESSOR DNA COMPLEX - UNDERSTANDING TUMORIGENIC MUTATIONS [J].
CHO, YJ ;
GORINA, S ;
JEFFREY, PD ;
PAVLETICH, NP .
SCIENCE, 1994, 265 (5170) :346-355
[5]
COOK N, 2002, CURR PROTOCOLS PR S, V27, P1981
[6]
Dahlquist F W, 1978, Methods Enzymol, V48, P270
[7]
FAN SJ, 1994, CANCER RES, V54, P5824
[8]
Pharmacological rescue of mutant p53 conformation and function [J].
Foster, BA ;
Coffey, HA ;
Morin, MJ ;
Rastinejad, F .
SCIENCE, 1999, 286 (5449) :2507-2510
[9]
The complexity of p53 modulation: emerging patterns from divergent signals [J].
Giaccia, AJ ;
Kastan, MB .
GENES & DEVELOPMENT, 1998, 12 (19) :2973-2983
[10]
GUBLER ML, 1995, BIOTECHNIQUES, V18, P1008